Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
FDA reports a supply disruption of Stereotactic Breast Biopsy Needles (KNW). Med-spas offering breast biopsy services must assess inventory and find alternatives.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Med-spas and aesthetics clinics that perform stereotactic breast biopsies should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; disruption is ongoing. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Supply disruption of Stereotactic Breast Biopsy Needles (product code KNW)
Who it affects
Med-spas and aesthetics clinics that perform stereotactic breast biopsies
What you must do
Review inventory, identify alternative biopsy methods or suppliers, and communicate with patients.
Deadline
Immediately; disruption is ongoing
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication
- The Safer Affordable Fuel-Efficient (SAFE) Vehicles Rule for Model Years 2021-2026 Passenger Cars and Light Trucks